On the evening of April 28th, Kangzhi Pharmaceutical disclosed its 2024 annual report and 2025 first quarter report. The report shows that in 2024, the company achieved a revenue of 473 million yuan and a net profit attributable to the parent company of 216 million yuan. During the reporting period, the net cash flow from operating activities increased by 1.08% year-on-year, reflecting the comprehensive effectiveness of the company’s resource optimization and allocation in sales collection management, inventory management, and fund coordination. In the first quarter of 2025, Kangzhi Pharmaceutical’s operating revenue reached 112 million yuan, with a net profit attributable to the parent company of -9.69 million yuan, a significant decrease of 79.16% year-on-year. The report states that the reason for the improvement in performance is a year-on-year decrease in sales expenses, resulting in a decrease in net profit loss. Among them, the net cash flow in the first quarter was 40.51 million yuan, an increase of 228.66% compared to the same period last year, due to a decrease in sales expenses year-on-year and the receipt of proposed performance payments from the controlling shareholder.
Scan code to share